Koordination und Qualität im Gesundheitswesen

Himmel, W., Kochen, M.M., Sorns, U., and Hummers-Pradier, E. (2003): Drug changes at the
interface between primary and secondary care. International Journal of Clinical Pharmacology
and Therapeutics, Vol. 42, S. 103-109.
Himmel, W., Lönker, B., and Kochen, M.M. (1998): Nonformulary drug requests at an academic
hospital in Germany – the role of general practitioners‘ long-term medication. European
Journal of Clinical Pharmacology, Vol. 54, S. 41-46.
Hirsch, L. (2004): Randomized clinical trails: What gets published, and when? Canadian
Medical Association Journal, Vol. 170, S. 481-483.
Hodges, B. (1995): Interactions with the pharmaceutical industry: experiences and attitudes of
psychiatry residents, interns, and clerks. Canadian Medical Association Journal, Vol. 153,
S. 553-559.
Hollis, S. und Campbell, F. (1999): What is meant by intention to treat analysis? Survey of
published randomised controlled trials. British Medical Journal, Vol. 319, S. 670-674.
Hueb, W., Soares, P.R., Gersh, B.J., Cesar, L.A.M., Luz, P.L., Puig, L.B., Martinez, E.M.,
Oliveira, S.A. and Ramires, J.A.F. (2004): The medicine, angioplasty, or surgery study
(MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for
multivessel coronary artery disease: One-year results. Journal of the American College of
Cardiology, Vol. 43, S. 1743-1751.
Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B. and Vittinghoff, E.
(1998): Randomized trial of estrogen plus progestin for secondary prevention of coronaryartery
atherosclerosis. New England Journal of Medicine, Vol. 343, S. 522-529.
Hurrelmann, K. und Kolip, P. (Hrsg.) (2002): Geschlecht, Gesundheit und Krankheit. Männer
und Frauen im Vergleich., Bern.
Hutchinson, J.M. and Foley, R.N. (1999): Method of physician remuneration and rates of antibiotic
prescription. Canadian Medical Association Journal, Vol. 160(7), S. 1013-1017.
Hutton, J., Borowitz, M., Oleksy, I. and Luce, B.R. (1994): The pharmaceutical industry and
health reform: Lessons from Europe. Health Affairs, Vol. 13(3), S. 98-111.
Iliffe, S. (2003): The failure of fund-holding in Britain’s National Health Service. Jahrbuch für
kritische Medizin, Bd. 38, S. 63-72.
IMS Health (2002): Retail Drug Monitor: 12 months to Jan 2002 (http://open.imshealth.com/
download/jan2002.pdf).
IMS Health (2003): Retail Drug Monitor: 12 months to Jan 2003 (http://open.imshealth.com/
download/jan2003.pdf).
IMS Health (2004): Internationaler Preisvergleich für Generika für den Verband Forschender
Arzneimittelhersteller e.V.
Ioannidis, J.P. (1998): Effect of the statistical significance of results on the time to completion
and publication of randomized efficacy trials. Journal of the American Medical Association,
Vol. 279, S. 281-286.
ISDB (International Society of Drug Bulletins) EU (2005): Berliner Deklaration zur Pharmakovigilanz,
Berlin, Januar 2005.
Jacobzone, S. (2000): Pharmaceutical policies in OECD countries: Reconciling social and industrial
goals. Labour market and social policy – Occational Papers No. 40. OECD.
748